Skip to content
value.today

Adaptin Bio, Inc.

Total raised
$2 M
1 round on record
Latest round
$2 M
Dec 2025
First round on record
Dec 2025
Today
Private
No later event on record

Funding rounds

1 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Adaptin Bio, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2025$2 MNo. 1Under $2 million

Adaptin Bio, Inc.: Raise no. 1, Dec 2025

Investors in this round

19 investors had bought by the notice of Jun 22, 2026: 19 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $4 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$229,440
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • L. Arthur Hewitt · Executive Officer · Chief Development Officer
  • Michael Roberts · Executive Officer, Director · President and Chief Executive Officer
  • Simon Arthur Pedder · Executive Officer, Director · Executive Chairman
  • Timothy Arthur Maness · Executive Officer · Chief Financial Officer
  • Anthony Nick Zook · Director
  • J. Nick Riehle · Director
  • Patrick Gallagher · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Laidlaw & Company (UK) Ltd. (CRD 119037) · New York, New YorkSold in CA, IL, KS, LA, MI, NC, NJ, NY, OR, SC, TX

Remarks in the notice

  • On fees: “Based on total amount sold as of date of first sale. In addition to the sales commissions, warrants to purchase up to an aggregate of 80,000 shares of our common stock will be issued to the placement agent at the final closing.”
  • On the use of proceeds: “Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering.”

Signed by Michael J. Roberts, President and Chief Executive Officer. Source: SEC Form D and 3 amendments, newest notice filed Jun 22, 2026. Read the notice at the SEC.

equitySEC
Feb 2025$13 MIssued in a merger or acquisition$10 to $50 million

Adaptin Bio, Inc.: Private sale, Feb 2025

Investors in this round

95 investors had bought by the notice of Feb 26, 2025: 95 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$13 M of $23 M offered; $10 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$475,558
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • L. Arthur Hewitt · Executive Officer · Chief Development Officer
  • Michael Roberts · Executive Officer, Director · President and Chief Executive Officer
  • Simon Arthur Pedder · Executive Officer, Director · Executive Chairman
  • Timothy Arthur Maness · Executive Officer · Chief Financial Officer
  • Anthony Nick Zook · Director
  • J. Nick Riehle · Director
  • Patrick Gallagher · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Laidlaw & Company (UK) Ltd. (CRD 119037) · New York, New YorkSold in AZ, CA, CO, FL, GA, IL, IN, KS, LA, MA, MD, MI, MT, NC, NH, NJ, NV, NY, OH, PA, SC, TX, WA, WI, and outside the US

Remarks in the notice

  • On fees: “Based on total amount sold as of date of first sale. In addition to the sales commissions, warrants to purchase an aggregate of 270,204 shares of our common stock were also issued to the placement agent.”
  • On the amounts: “Amounts include securities to be acquired upon the exercise of warrants.”
  • On the use of proceeds: “Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering.”
  • On a merger: “Initial sale occurred with closing of merger involving Unite Acquisition 1 Corp. (Unite), a subsidiary of Unite, and Adaptin Bio, Inc. (Private Adaptin). Private Adaptin survived as subsidiary of Unite and was renamed. Unite renamed Adaptin Bio, Inc.”

Signed by Michael J. Roberts, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 26, 2025. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Adaptin Bio, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2026).

    SEC Form D · Jun 2026

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2026

That is all the official record says: Adaptin Bio, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Adaptin Bio, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 19 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Adaptin Bio, Inc.
NameRoleNamed in
L. Arthur HewittChief Development OfficerJun 2026
Michael RobertsPresident and Chief Executive OfficerJun 2026
Simon Arthur PedderExecutive ChairmanJun 2026
Timothy Arthur ManessChief Financial OfficerJun 2026
Anthony Nick ZookDirectorJun 2026
J. Nick RiehleDirectorJun 2026
Michael RobertsPresident and Chief Executive OfficerJun 2026
Patrick GallagherDirectorJun 2026
Simon Arthur PedderExecutive ChairmanJun 2026